Market Overview

UPDATE: Goldman Sachs Raises PT to $6.60 on Boston Scientific Following Q4 Takeaways

Share:
Related BSX
Needham Calls Boston Scientific's Results Just 'Decent'
Boston Scientific Posts In-Line Q1 Earnings, Issues Weak Outlook
Boston Scientific on the hook for $100M in Delaware transvaginal mesh trial (Seeking Alpha)

Goldman Sachs maintained Boston Scientific Corporation (NYSE: BSX) with a Sell rating and raised the price target from $5.20 to $6.60.

Goldman Sachs noted, "Following 4Q12 results, we adjust our 2013-2016E EPS to reflect: (1) increased sales across most businesses, aside from CRM; (2) revised gross margin assumptions; (3) higher operating expenses; (4) higher interest expense; and (5) increased share repurchases. Still, our revised 2013 sales estimate is now at the low end of guidance (-1.6% vs. the guidance midpoint at -0.7%), as we remain cautious on Boston's business exposure and relative share position."

Boston Scientific closed at $7.10 on Tuesday.

Latest Ratings for BSX

DateFirmActionFromTo
Apr 2015BarclaysMaintainsOverweight
Apr 2015Leerink SwannMaintainsOutperform
Apr 2015RBC CapitalMaintainsOutperform

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Analyst Ratings

 

Related Articles (BSX)

Around the Web, We're Loving...

Get Benzinga's Newsletters